MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Chaturvedi P, Singh AP, Batra SK. Structure, evolution, and biology of the MUC4 mucin. FASEB J. 2008;22:966–981.
   PubMed Web of Science ®Google Scholar
• Moniaux N, Escande F, Porchet N, et al. Structural organization and classification of the human mucin genes. Front Biosci. 2001;6:D1192–206.
   PubMed Web of Science ®Google Scholar
• Kaur S, Kumar S, Momi N, et al. Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol. 2013;10:607–620.
   PubMed Web of Science ®Google Scholar
• Andrianifahanana M, Moniaux N, Schmied BM, et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res. 2001;7:4033–4040.
   PubMed Web of Science ®Google Scholar
• Balagué C, Audié J-P, Porchet N, et al. In situ hybridization shows distinct patterns of mucin gene expression in normal, benign, and malignant pancreas tissues. Gastroenterology. 1995;109:953–964.
   PubMed Web of Science ®Google Scholar
• Hollingsworth MA, Strawhecker JM, Caffrey TC, et al. Expression of MUC1, MUC2, MUC3 and MUC4 mucin mrnas in human pancreatic and intestinal tumor cell lines. Int J Cancer. 1994;57:198–203.
   PubMed Web of Science ®Google Scholar
• Singh AP, Moniaux N, Chauhan SC, et al. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res. 2004;64:622–630.
   PubMed Web of Science ®Google Scholar
• Chaturvedi P, Singh AP, Moniaux N, et al. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res. 2007;5:309–320.
   PubMed Web of Science ®Google Scholar
• Swartz MJ, Batra SK, Varshney GC, et al. MUC4 Expression Increases Progressively in Pancreatic Intraepithelial Neoplasia. Am J Clin Pathol. 2002;117:791–796.
   PubMed Web of Science ®Google Scholar
• Bafna S, Singh AP, Moniaux N, et al. MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. Cancer Res. 2008;68:9231–9238.
   PubMed Web of Science ®Google Scholar
• Moniaux N, Chaturvedi P, Varshney GC, et al. Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells. Br J Cancer. 2007;97:345–357.
   PubMed Web of Science ®Google Scholar
• Senapati S, Chaturvedi P, Chaney WG, et al. Novel interaction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer. Clin Cancer Res. 2011;17:267–274.
   PubMed Web of Science ®Google Scholar
• Mimeault M, Johansson SL, Senapati S, et al. MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. Cancer Lett. 2010;295:69–84.
   PubMed Web of Science ®Google Scholar
• Skrypek N, Duchene B, Hebbar M, et al. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene. 2013;32:1714–1723.
   PubMed Web of Science ®Google Scholar
• Wissniowski TT, Meister S, Hahn EG, et al. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells. Int J Oncol. 2012;40:1581–1589.
   PubMed Web of Science ®Google Scholar
• Bafna S, Kaur S, Momi N, et al. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin. Br J Cancer. 2009;101:1155–1161.
   PubMed Web of Science ®Google Scholar
• Seshacharyulu P, Ponnusamy MP, Rachagani S, et al. Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. Oncotarget. 2015;6:5164–5181.
   PubMed Web of Science ®Google Scholar
• Senapati S, Gnanapragassam VS, Moniaux N, et al. Role of MUC4-NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells. Oncogene. 2012;31:3346–3356.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang JJ, Liang WB, et al. Pancreatic cancer counterattack: MUC4 mediates Fas-independent apoptosis of antigen-specific cytotoxic T lymphocyte. Oncol Rep. 2014;31:1768–1776.
   PubMed Web of Science ®Google Scholar
• Saitou M, Goto M, Horinouchi M, et al. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. Journal of Clinical Pathology. 2005;58:845–852.
   PubMed Web of Science ®Google Scholar
• Moniaux N, Nollet S, Porchet N, et al. Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. Biochem J. 1999;338(Pt 2):325–333.
   PubMed Web of Science ®Google Scholar
• Moniaux N, Escande F, Batra SK, et al. Alternative splicing generates a family of putative secreted and membrane-associated MUC4 mucins. Eur J Biochem. 2000;267:4536–4544.
   PubMedGoogle Scholar
• Buisine MP, Devisme L, Copin MC, et al. Developmental mucin gene expression in the human respiratory tract. Am J Respir Cell Mol Biol. 1999;20:209–218.
   PubMed Web of Science ®Google Scholar
• Buisine MP, Devisme L, Degand P, et al. Developmental mucin gene expression in the gastroduodenal tract and accessory digestive glands. II. Duodenum and liver, gallbladder, and pancreas. J Histochem Cytochem. 2000;48:1667–1676.
   PubMed Web of Science ®Google Scholar
• Reid CJ, Harris A. Developmental expression of mucin genes in the human gastrointestinal system. Gut. 1998;42:220–226.
   PubMed Web of Science ®Google Scholar
• Guillem P, Billeret V, Buisine MP, et al. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer. 2000;88:856–861.
   PubMed Web of Science ®Google Scholar
• Liu B, Offner GD, Nunes DP, et al. MUC4 is a major component of salivary mucin MG1 secreted by the human submandibular gland. Biochem Biophys Res Commun. 1998;250:757–761.
   PubMed Web of Science ®Google Scholar
• Zhang J, Perez A, Yasin M, et al. Presence of MUC4 in human milk and at the luminal surfaces of blood vessels. J Cell Physiol. 2005;204:166–177.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Begne M, Lu B, Han X, et al. Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT). J Proteome Res. 2009;8:1304–1314.
   PubMed Web of Science ®Google Scholar
• Yonezawa S, Higashi M, Yamada N, et al. Precursor Lesions of Pancreatic Cancer. Gut and Liver. 2008;2:137–154.
   PubMed Web of Science ®Google Scholar
• Jhala N, Jhala D, Vickers SM, et al. Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol. 2006;126:572–579.
   PubMed Web of Science ®Google Scholar
• Ansari D, Urey C, Gundewar C, et al. Comparison of MUC4 expression in primary pancreatic cancer and paired lymph node metastases. Scand J Gastroenterol. 2013;48:1183–1187.
   PubMed Web of Science ®Google Scholar
• Chugh S, Gnanapragassam VS, Jain M, et al. Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets. Biochim Biophys Acta. 2015;1856:211–225.
   PubMed Web of Science ®Google Scholar
• Choudhury A, Moniaux N, Winpenny JP, et al. Human MUC4 mucin cDNA and its variants in pancreatic carcinoma. J Biochem. 2000;128:233–243.
   PubMed Web of Science ®Google Scholar
• Choudhury A, Moniaux N, Ringel J, et al. Alternate splicing at the 3ʹ-end of the human pancreatic tumor-associated mucin MUC4 cDNA. Teratog Carcinog Mutagen. 2001;21:83–96.
   PubMedGoogle Scholar
• Kumar S, Cruz E, Joshi S, et al. Genetic Variants of Mucins: unexplored Conundrum. Carcinogenesis. 2016. [Epub ahead of print] PMID: 27838635.
   Web of Science ®Google Scholar
• Carraway KL 3rd, Rossi EA, Komatsu M, et al. An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling. J Biol Chem. 1999;274:5263–5266.
   PubMed Web of Science ®Google Scholar
• Lakshmanan I, Seshacharyulu P, Haridas D, et al. Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. Oncotarget. 2015;6:21085–21099.
   PubMed Web of Science ®Google Scholar
• Jonckheere N, Skrypek N, Merlin J, et al. The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways. Plos ONE. 2012;7:e32232.
   PubMed Web of Science ®Google Scholar
• Rachagani S, Macha MA, Ponnusamy MP, et al. MUC4 potentiates invasion and metastasis of pancreatic cancer cells through stabilization of fibroblast growth factor receptor 1. Carcinogenesis. 2012;33:1953–1964.
   PubMed Web of Science ®Google Scholar
• Singh AP, Chauhan SC, Andrianifahanana M, et al. MUC4 expression is regulated by cystic fibrosis transmembrane conductance regulator in pancreatic adenocarcinoma cells via transcriptional and post-translational mechanisms. Oncogene. 2007;26:30–41.
   PubMed Web of Science ®Google Scholar
• Singh AP, Chaturvedi P, Batra SK. Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res. 2007;67:433–436.
   PubMed Web of Science ®Google Scholar
• Komatsu M, Yee L, Carraway KL. Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells. Cancer Res. 1999;59:2229–2236.
   PubMed Web of Science ®Google Scholar
• Basso D, Gnatta E Plenani M. Pancreatic cancer fostered immunosuppression privileges tumor growth and progression. J Clin Cell Immunol. 2014;5:278–293.
   Google Scholar
• Inman KS, Francis AA, Murray NR. Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol. 2014;20:11160–11181.
   PubMed Web of Science ®Google Scholar
• Geng Y, Marshall JR, King MR. Glycomechanics of the metastatic cascade: tumor cell-endothelial cell interactions in the circulation. Ann Biomed Eng. 2012;40:790–805.
   PubMed Web of Science ®Google Scholar
• Tang J, Zhu Y, Xie K, et al. The role of the AMOP domain in MUC4/Y-promoted tumour angiogenesis and metastasis in pancreatic cancer. J Exp Clin Cancer Res. 2016;35:91.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang JJ, Peng YP, et al. NIDO, AMOP and vWD domains of MUC4 play synergic role in MUC4 mediated signaling. Oncotarget. 2017;8:10385–10399.
   PubMed Web of Science ®Google Scholar
• Hagmann W, Faissner R, Schnolzer M, et al. Membrane Drug Transporters and Chemoresistance in Human Pancreatic Carcinoma. Cancers. 2011;3:106–125.
   Google Scholar
• Ansari D, Urey C, Hilmersson KS, et al. Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression. Anticancer Res. 2014;34:5269–5276.
   PubMed Web of Science ®Google Scholar
• Urey C, Andersson B, Ansari D, et al. Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. Scand J Gastroenterol. 2017;52:595–600.
   PubMed Web of Science ®Google Scholar
• Perrais M, Pigny P, Ducourouble MP, et al. Characterization of human mucin gene MUC4 promoter: importance of growth factors and proinflammatory cytokines for its regulation in pancreatic cancer cells. J Biol Chem. 2001;276:30923–30933.
   PubMed Web of Science ®Google Scholar
• Chapela PJ, Broaddus RR, Hawkins SM, et al. Cytokine stimulation of MUC4 expression in human female reproductive tissue carcinoma cell lines and endometrial cancer. J Cell Biochem. 2015;116:2649–2657.
   PubMed Web of Science ®Google Scholar
• Andrianifahanana M, Agrawal A, Singh AP, et al. Synergistic induction of the MUC4 mucin gene by interferon-gamma and retinoic acid in human pancreatic tumour cells involves a reprogramming of signalling pathways. Oncogene. 2005;24:6143–6154.
   PubMed Web of Science ®Google Scholar
• Andrianifahanana M, Chauhan SC, Choudhury A, et al. MUC4-expressing pancreatic adenocarcinomas show elevated levels of both T1 and T2 cytokines: potential pathobiologic implications. Am J Gastroenterol. 2006;101:2319–2329.
   PubMed Web of Science ®Google Scholar
• Jonckheere N, Perrais M, Mariette C, et al. A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis. Oncogene. 2004;23:5729–5738.
   PubMed Web of Science ®Google Scholar
• Choudhury A, Singh RK, Moniaux N, et al. Retinoic acid-dependent transforming growth factor-beta 2-mediated induction of MUC4 mucin expression in human pancreatic tumor cells follows retinoic acid receptor-alpha signaling pathway. J Biol Chem. 2000;275:33929–33936.
   PubMed Web of Science ®Google Scholar
• Damera G, Xia B, Ancha HR, et al. IL-9 modulated MUC4 gene and glycoprotein expression in airway epithelial cells. Biosci Rep. 2006;26:55–67.
   PubMed Web of Science ®Google Scholar
• Damera G, Xia B, Sachdev GP. IL-4 induced MUC4 enhancement in respiratory epithelial cells in vitro is mediated through JAK-3 selective signaling. Respir Res. 2006;7:39.
   PubMed Web of Science ®Google Scholar
• Mejias-Luque R, Peiro S, Vincent A, et al. IL-6 induces MUC4 expression through gp130/STAT3 pathway in gastric cancer cell lines. Biochim Biophys Acta. 2008;1783:1728–1736.
   PubMed Web of Science ®Google Scholar
• Andoh A, Shioya M, Nishida A, et al. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. J Immunol. 2009;183:687–695.
   PubMed Web of Science ®Google Scholar
• Vasseur R, Skrypek N, Duchêne B, et al. The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling pathways. Biochimica Et Biophysica Acta (BBA) - Gene Regulatory Mechanisms. 2015;1849:1375–1384.
   Web of Science ®Google Scholar
• Yamada N, Kitamoto S, Yokoyama S, et al. Epigenetic regulation of mucin genes in human cancers. Clinical Epigenetics. 2011;2:85–96.
   PubMed Web of Science ®Google Scholar
• Yamada N, Nishida Y, Tsutsumida H, et al. Promoter CpG methylation in cancer cells contributes to the regulation of MUC4. British Journal of Cancer. 2009;100:344–351.
   PubMed Web of Science ®Google Scholar
• Vincent A, Ducourouble M-P, Van Seuningen I. Epigenetic regulation of the human mucin gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone modifications mediated by DNA methyltransferases and histone deacetylases. The FASEB Journal. 2008;22:3035–3045.
   PubMed Web of Science ®Google Scholar
• Yokoyama S, Higashi M, Kitamoto S, et al. Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas. Oncotarget. 2016;7:42553–42565.
   PubMed Web of Science ®Google Scholar
• Kumar S, Das S, Rachagani S, et al. NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer. Oncogene. 2015;34:4879–4889.
   PubMed Web of Science ®Google Scholar
• Pai P, Rachagani S, Lakshmanan I, et al. The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma. Molecular Oncology. 2016;10:224–239.
   PubMed Web of Science ®Google Scholar
• Joshi S, Cruz E, Rachagani S, et al. Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer. Molecular Oncology. 2016;10:1063–1077.
   PubMed Web of Science ®Google Scholar
• Joshi S, Kumar S, Ponnusamy MP, et al. Hypoxia-induced oxidative stress promotes MUC4 degradation via autophagy to enhance pancreatic cancer cells survival. Oncogene. 2016;35:5882–5892.
   PubMed Web of Science ®Google Scholar
• Chaturvedi P, Singh AP, Chakraborty S, et al. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res. 2008;68:2065–2070.
   PubMed Web of Science ®Google Scholar
• Li Y, Wu C, Chen T, et al. Effects of RNAi-mediated MUC4 gene silencing on the proliferation and migration of human pancreatic carcinoma BxPC-3 cells. Oncol Rep. 2016;36:3449–3455.
   PubMed Web of Science ®Google Scholar
• Sepp-Lorenzino L, Ruddy MK. Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides. Clin Pharmacol Ther. 2008;84:628–632.
   PubMed Web of Science ®Google Scholar
• Watts JK, Corey DR. Gene silencing by siRNAs and antisense oligonucleotides in the laboratory and the clinic. The Journal of Pathology. 2012;226:365–379.
   PubMed Web of Science ®Google Scholar
• Wang Y, Kumar S, Rachagani S, et al. Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis. Biomaterials. 2016;101:108–120.
   PubMed Web of Science ®Google Scholar
• MacFarlane L-A, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Current Genomics. 2010;11:537–561.
   PubMed Web of Science ®Google Scholar
• Rachagani S, Macha MA, Menning MS, et al. Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model. Oncotarget. 2015;6:40295–40309.
   PubMed Web of Science ®Google Scholar
• Yang K, He M, Cai Z, et al. A decrease in miR-150 regulates the malignancy of pancreatic cancer by targeting c-Myb and MUC4. Pancreas. 2015;44:370–379.
   PubMed Web of Science ®Google Scholar
• Srivastava SK, Bhardwaj A, Singh S, et al. MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis. 2011;32:1832–1839.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan P, Mohr AM, Grandgenett PM, et al. MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer. Plos One. 2013;8:e73356.
   PubMed Web of Science ®Google Scholar
• Lahdaoui F, Delpu Y, Vincent A, et al. miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer. Oncogene. 2015;34:780–788.
   PubMed Web of Science ®Google Scholar
• Arora S, Swaminathan SK, Kirtane A, et al. Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy. Int J Nanomedicine. 2014;9:2933–2942.
   PubMed Web of Science ®Google Scholar
• Gollub EG, Waksman H, Goswami S, et al. Mucin genes are regulated by estrogen and dexamethasone. Biochem Biophys Res Commun. 1995;217:1006–1014.
   PubMed Web of Science ®Google Scholar
• Seo KY, Chung SH, Lee JH, et al. Regulation of membrane-associated mucins in the human corneal epithelial cells by dexamethasone. Cornea. 2007;26:709–714.
   PubMed Web of Science ®Google Scholar
• Bai CH, Song SY, Kim YD. Effect of glucocorticoid on the MUC4 gene in nasal polyps. Laryngoscope. 2007;117:2169–2173.
   PubMed Web of Science ®Google Scholar
• Martinez-Anton A, De Bolos C, Alobid I, et al. Corticosteroid therapy increases membrane-tethered while decreases secreted mucin expression in nasal polyps. Allergy. 2008;63:1368–1376.
   PubMed Web of Science ®Google Scholar
• Woo HJ, Bae CH, Song SY, et al. Expression of membrane-bound mucins in human nasal mucosa: different patterns for MUC4 and MUC16. Arch Otolaryngol Head Neck Surg. 2010;136:603–609.
   PubMedGoogle Scholar
• Macha MA, Krishn SR, Jahan R, et al. Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer. Cancer Treat Rev. 2015;41:277–288.
   PubMed Web of Science ®Google Scholar
• Macha MA, Rachagani S, Gupta S, et al. Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling. Cancer Lett. 2013;341:166–177.
   PubMed Web of Science ®Google Scholar
• Ahn DW, Seo JK, Lee SH, et al. Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer. Pancreas. 2012;41:1048–1057.
   PubMed Web of Science ®Google Scholar
• Woo CC, Kumar AP, Sethi G, et al. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol. 2012;83:443–451.
   PubMed Web of Science ®Google Scholar
• Torres MP, Ponnusamy MP, Chakraborty S, et al. Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol Cancer Ther. 2010;9:1419–1431.
   PubMed Web of Science ®Google Scholar
• Wu ZH, Chen Z, Shen Y, et al. Anti-metastasis effect of thymoquinone on human pancreatic cancer. Yao Xue Xue Bao. 2011;46:910–914.
   PubMedGoogle Scholar
• Banerjee S, Azmi AS, Padhye S, et al. Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer. Pharm Res. 2010;27:1146–1158.
   PubMed Web of Science ®Google Scholar
• Torres MP, Rachagani S, Purohit V, et al. Graviola: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. Cancer Lett. 2012;323:29–40.
   PubMed Web of Science ®Google Scholar
• Bailey P, Chang DK, Forget MA, et al. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Sci Rep. 2016;6:35848.
   PubMed Web of Science ®Google Scholar
• Rachagani S, Torres MP, Kumar S, et al. Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. J Hematol Oncol. 2012;5:68.
   PubMed Web of Science ®Google Scholar
• Pedersen JW, Gentry-Maharaj A, Nøstdal A, et al. Cancer-associated autoantibodies to MUC1 and MUC4-a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. Int J Cancer. 2014;134:2180–2188.
   PubMed Web of Science ®Google Scholar
• Wei J, Gao W, Wu J, et al. Dendritic cells expressing a combined PADRE/MUC4-derived polyepitope DNA vaccine induce multiple cytotoxic T-cell responses. Cancer Biother Radiopharm. 2008;23:121–128.
   PubMed Web of Science ®Google Scholar
• Chen J, Guo XZ, Li HY, et al. Generation of CTL responses against pancreatic cancer in vitro using dendritic cells co-transfected with MUC4 and survivin RNA. Vaccine. 2013;31:4585–4590.
   PubMed Web of Science ®Google Scholar
• Brinas RP, Sundgren A, Sahoo P, et al. Design and synthesis of multifunctional gold nanoparticles bearing tumor-associated glycopeptide antigens as potential cancer vaccines. Bioconjug Chem. 2012;23:1513–1523.
   PubMed Web of Science ®Google Scholar
• Chames P, Kerfelec B, Baty D. Therapeutic antibodies for the treatment of pancreatic cancer. Scientific World J. 2010;10:1107–1120.
   Web of Science ®Google Scholar
• Huang ZQ, Buchsbaum DJ. Monoclonal antibodies in the treatment of pancreatic cancer. Immunotherapy. 2009;1:223–229.
   PubMed Web of Science ®Google Scholar
• Moniaux N, Varshney GC, Chauhan SC, et al. Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. J Histochem Cytochem. 2004;52:253–261.
   PubMed Web of Science ®Google Scholar
• Jain M, Venkatraman G, Moniaux N, et al. Monoclonal antibodies recognizing the non-tandem repeat regions of the human mucin MUC4 in pancreatic cancer. Plos One. 2011;6:e23344.
   PubMed Web of Science ®Google Scholar
• Wang G, Lipert RJ, Jain M, et al. Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering. Anal Chem. 2011;83:2554–2561.
   PubMed Web of Science ®Google Scholar